{
    "clinical_study": {
        "@rank": "110845", 
        "arm_group": [
            {
                "arm_group_label": "7-day quadruple therapy", 
                "arm_group_type": "Experimental", 
                "description": "pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days"
            }, 
            {
                "arm_group_label": "10-day sequential therapy", 
                "arm_group_type": "Experimental", 
                "description": "pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days"
            }, 
            {
                "arm_group_label": "7-day standard triple therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day\n      quadruple therapies for H. pylori infection in Taiwan. Consecutive H. pylori-infected\n      patients were randomly assigned to a 7-day standard triple therapy (pantoprazole,\n      clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and\n      amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a\n      further 5 days) or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and\n      metronidazole for 7 days). The end point is to evaluate the effectiveness of Helicobacter\n      pylori eradication rates between three groups."
        }, 
        "brief_title": "Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Helicobacter Pylori Infection", 
        "condition_browse": {
            "mesh_term": "Helicobacter Infections"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to compare the effectiveness of three H. pylori eradication\n      regimens: 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7\n      days), 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by\n      pantoprazole, clarithromycin and metronidazole for a further 5 days) and 7-day quadruple\n      therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days) in Taiwan.\n\n      A total of 306 subjects are enrolled into this study.\n\n      H. pylori-infected patients are randomized to a 7-day standard triple therapy, a 10-day\n      sequential therapy, or a 7-day quadruple therapy. Eradication efficacy is assessed by a\n      follow-up endoscopy with rapid urease test and histological examination eight weeks after\n      the H. pylori therapy. The eradication rates of three groups will be compared."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Consecutive H. pylori-infected outpatients, at least 20 years of age, with\n             endoscopically proven peptic ulcer diseases or gastritis\n\n        Exclusion Criteria:\n\n          -  previous H. pylori-eradication therapy\n\n          -  ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks\n\n          -  patients with allergic history to the medications used\n\n          -  patients with previous gastric surgery\n\n          -  the coexistence of serious concomitant illness (for example, decompensated liver\n             cirrhosis, uremia)\n\n          -  pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "306", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769365", 
            "org_study_id": "VGHKS99-CT7-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "7-day quadruple therapy", 
                "description": "pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days", 
                "intervention_name": "7-day quadruple therapy", 
                "intervention_type": "Drug", 
                "other_name": "Pantoprazole, amoxicillin, clarithromycin, metronidazole"
            }, 
            {
                "arm_group_label": "10-day sequential therapy", 
                "description": "pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days", 
                "intervention_name": "10-day sequential therapy", 
                "intervention_type": "Drug", 
                "other_name": "sequential group"
            }, 
            {
                "arm_group_label": "7-day standard triple therapy", 
                "description": "pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days", 
                "intervention_name": "7-day standard triple therapy", 
                "intervention_type": "Drug", 
                "other_name": "pantoprazole, clarithromycin, amoxicillin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Clarithromycin", 
                "Metronidazole", 
                "Pantoprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Helicobacter pylori infection", 
        "lastchanged_date": "January 14, 2013", 
        "location": {
            "contact": {
                "email": "williamhsup@yahoo.com.tw", 
                "last_name": "Ping-I Hsu, MD, PHD", 
                "phone": "+886-7-342-2121", 
                "phone_ext": "2075"
            }, 
            "contact_backup": {
                "email": "khlai@isca.vghks.gov.tw", 
                "last_name": "Kwok-Hung Lai, MD", 
                "phone": "+886-7-3422121", 
                "phone_ext": "2075"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung city", 
                    "country": "Taiwan", 
                    "zip": "813"
                }, 
                "name": "Kaohsiung Veterans General Hospital"
            }, 
            "investigator": {
                "last_name": "Ping-I Hsu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan", 
        "overall_contact": {
            "email": "williamhsup@yahoo.com.tw", 
            "last_name": "Ping-I Hsu, MD", 
            "phone": "+886-7-342-2121", 
            "phone_ext": "8233"
        }, 
        "overall_contact_backup": {
            "email": "joywu@cc.kmu.edu.tw", 
            "last_name": "Jeng-Yih Wu, MD", 
            "phone": "+886-7-3121101"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "eradication rate", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769365"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaohsiung Veterans General Hospital.", 
            "investigator_full_name": "Ping-I (William) Hsu, M.D.", 
            "investigator_title": "Chief of Division of Gastroenterology; Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Kaohsiung Veterans General Hospital.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaohsiung Veterans General Hospital.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}